Nicole La Brosse Halozyme Therapeutics, Inc. (HALO) insider trading activity

Nicole La Brosse is SVP, CHIEF FINANCIAL OFFICER of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 22,079 shares of HALO, which is worth approximately $1.58 Million. The most recent transaction as insider was on Feb 15, 2023, when has been sold 621 shares (Common Stock) at a price of $49.2 per share, resulting in proceeds of $30,553. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 22.1K

30.79% 3M change

42.63% 12M change

Total Value Held $1.58 Million

Nicole LaBrosse Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 15 2023	SELL Payment of exercise price or tax liability	$30,553 $49.2 p/Share	621 Reduced 8.72%	6,497 Common Stock
Feb 15 2023	BUY Exercise of conversion of derivative security	-	1,254 Added 14.98%	7,118 Common Stock
Feb 12 2023	SELL Payment of exercise price or tax liability	$33,314 $48.92 p/Share	681 Reduced 10.4%	5,864 Common Stock
Feb 12 2023	BUY Exercise of conversion of derivative security	-	1,389 Added 17.51%	6,545 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$68,096 $48.92 p/Share	1,392 Reduced 21.26%	5,156 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	-	2,503 Added 27.65%	6,548 Common Stock
Nov 15 2022	SELL Open market or private sale	$268,750 $53.75 p/Share	5,000 Reduced 55.28%	4,045 Common Stock
Feb 15 2022	SELL Payment of exercise price or tax liability	$14,908 $34.43 p/Share	433 Reduced 4.57%	9,045 Common Stock
Feb 15 2022	BUY Exercise of conversion of derivative security	-	1,255 Added 11.69%	9,478 Common Stock
Feb 14 2022	SELL Payment of exercise price or tax liability	$14,364 $33.64 p/Share	427 Reduced 4.94%	8,223 Common Stock
Feb 14 2022	BUY Exercise of conversion of derivative security	-	1,256 Added 12.68%	8,650 Common Stock
Feb 12 2022	SELL Payment of exercise price or tax liability	$17,305 $34.2 p/Share	506 Reduced 6.41%	7,394 Common Stock
Feb 12 2022	BUY Exercise of conversion of derivative security	-	1,389 Added 14.95%	7,900 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$35,813 $34.94 p/Share	1,025 Reduced 13.6%	6,511 Common Stock
Feb 10 2022	BUY Exercise of conversion of derivative security	-	2,503 Added 24.93%	7,536 Common Stock

Nicole La Brosse

SVP, CHIEF FINANCIAL OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Value

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

Operation

Value

Type

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO

Account